ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,101.24
-0.29%
US Tech 100
21,156.80
-0.70%
다우존스 지수
44,424.25
-0.32%
Bitcoin
104,983.67
0.24%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Inozyme Pharma Inc (INZY)

  7. Inozyme Pharma Inc (INZY) 뉴스

Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

NASDAQ
1.41
0.09
(6.82%)
마감 26 1월 6:00AM
15분 지연
1.4399
0.0299
(2.12%)
시간외 거래: 9:02AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

INZY 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
10 1월 2025
INZY (6.82%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
10 12월 2024
INZY (6.82%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
09 11월 2024
INZY (6.82%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
05 11월 2024
INZY (6.82%)

Form 8-K - Current report
Edgar (US Regulatory)
05 11월 2024
INZY (6.82%)

Form 8-K - Current report
Edgar (US Regulatory)
25 10월 2024
INZY (6.82%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
25 10월 2024
INZY (6.82%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 10월 2024
INZY (6.82%)

INZY Discussion

게시물 보기
tj9938 tj9938 2 월 전
Taking a beating this week. 
👍️0
Monksdream Monksdream 5 월 전
INZY under $6
👍️0
AJ Freely AJ Freely 1 년 전
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 2 년 전
INZY new 52 week high
👍️0
INFINITI INFINITI 2 년 전
Loading
👍️0
Jess070283 Jess070283 2 년 전
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 2 년 전
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 2 년 전
Quietest board out there
👍️0
ErnieBilco ErnieBilco 3 년 전
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 3 년 전
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 3 년 전
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 3 년 전
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 3 년 전
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 3 년 전
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 3 년 전
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 3 년 전
PT > 33.00
👍️0
crudeoil24 crudeoil24 3 년 전
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

최근 히스토리

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유